Qiagen reported strong Q4 results, with robust demand for non-COVID offerings, which is guided to continue in 2022. This overshadowed the moderation in COVID-19 sales. Although, COVID-19-driven sales are expected to witness a significant decline, resulting in an overall sales decline guided for 2022. Besides these results validating our positive stock recommendation, there’s also a promising read-across for other testing firms in our coverage.
